Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
A61K-039/09
C07K-014/315
C07K-016/12
A61K-039/00
출원번호
US-0943484
(2013-07-16)
등록번호
US-9127050
(2015-09-08)
발명자
/ 주소
Scully, Ingrid Lea
Anderson, Annaliesa Sybil
Hagen, Michael
Olmsted, Stephen Bruce
Cleary, Paul Patrick
출원인 / 주소
Regents of the University of Minnesota
대리인 / 주소
Viksnins Harris & Padys PLLP
인용정보
피인용 횟수 :
0인용 특허 :
47
초록▼
A number of β-hemolytic streptococci polynucleotides and polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizin
A number of β-hemolytic streptococci polynucleotides and polypeptides, particularly Streptococcus pyogenes polypeptides and polynucleotides, are described. Two or more of the polypeptides of the invention can be formulated for use as immunogenic compositions. Also disclosed are methods for immunizing against and reducing infection caused by β-hemolytic streptococci.
대표청구항▼
1. An immunogenic composition comprising an effective amount of a first polypeptide encoded by a nucleic acid set forth as SEQ ID NO:1 and an effective amount of a second polypeptide encoded by a nucleic acid set forth as SEQ ID NO:7. 2. The immunogenic composition of claim 1, which further comprise
1. An immunogenic composition comprising an effective amount of a first polypeptide encoded by a nucleic acid set forth as SEQ ID NO:1 and an effective amount of a second polypeptide encoded by a nucleic acid set forth as SEQ ID NO:7. 2. The immunogenic composition of claim 1, which further comprises a physiologically-acceptable vehicle. 3. The immunogenic composition of claim 1, which further comprises an effective amount of an adjuvant. 4. The immunogenic composition of claim 1 wherein each polypeptide is capable of generating an antibody that specifically recognizes said polypeptide, and wherein the amount of said immunogenic composition is effective to prevent or ameliorate colonization or infection by β-hemolytic streptococci in a susceptible animal. 5. The immunogenic composition of claim 4, which further comprises a physiologically-acceptable vehicle. 6. The immunogenic composition of claim 4, which further comprises an effective amount of an adjuvant. 7. The immunogenic composition of claim 4, wherein the β-hemolytic streptococci is Group A streptococci. 8. The immunogenic composition of claim 7, wherein the Group A streptococci is Streptococcus pyogenes. 9. An immunogenic composition comprising an effective amount of a first isolated polypeptide having an amino acid sequence of SEQ ID NO:2 and an effective amount of a second isolated polypeptide having an amino acid sequence of SEQ ID NO:8. 10. The immunogenic composition of claim 9, which further comprises a physiologically-acceptable vehicle. 11. The immunogenic composition of claim 9, which further comprises an effective amount of an adjuvant. 12. The immunogenic composition of claim 9, wherein each polypeptide is capable of generating an antibody that specifically recognizes said polypeptide, and wherein the amount of said immunogenic composition is effective to prevent or ameliorate colonization or infection by β-hemolytic streptococci in a susceptible animal. 13. The immunogenic composition of claim 12, which further comprises a physiologically-acceptable vehicle. 14. The immunogenic composition of claim 12, which further comprises an effective amount of an adjuvant. 15. The immunogenic composition of claim 12, wherein the β-hemolytic streptococci is Group A streptococci. 16. The immunogenic composition of claim 15, wherein the Group A streptococci is Streptococcus pyogenes. 17. A method of treating a susceptible animal against colonization or infection by β-hemolytic streptococci comprising administering to the animal an effective amount of the immunogenic composition of claim 1, wherein each polypeptide is capable of generating an antibody specific to said polypeptide, and wherein the amount of said immunogenic composition is effective to ameliorate colonization or infection by β-hemolytic streptococci in the susceptible animal. 18. The method of claim 17, wherein the immunogenic composition is administered by subcutaneous injection, by intramuscular injection, by oral ingestion, intranasally, or combinations thereof. 19. The method of claim 17 wherein the β-hemolytic streptococci is Group A streptococci. 20. The method of claim 19 wherein the Group A streptococci is Streptococcus pyogenes. 21. The method of claim 17 wherein the animal is a human. 22. A method of treating a susceptible animal against colonization or infection by β-hemolytic streptococci comprising administering to the animal an effective amount of the immunogenic composition of claim 9, wherein each polypeptide is capable of generating an antibody specific to said polypeptide, and wherein the amount of said immunogenic composition is effective to ameliorate colonization or infection by β-hemolytic streptococci in the susceptible animal. 23. The method of claim 22, wherein the immunogenic composition is administered by subcutaneous injection, by intramuscular injection, by oral ingestion, intranasally, or combinations thereof. 24. The method of claim 22 wherein the β-hemolytic streptococci is Group A streptococci. 25. The method of claim 24 wherein the Group A streptococci is Streptococcus pyogenes. 26. The method of claim 22 wherein the animal is a human. 27. The immunogenic composition of claim 1, further an effective amount of a polypeptide encoded by (a) a nucleic acid set forth as SEQ ID NO: 3, SEQ ID NO: 5,(b) a nucleic acid set forth as SEQ ID NO: 9, or(c) a nucleic acid set forth as SEQ ID NO: 5 and a nucleic acid set forth as SEQ ID NO: 9. 28. The immunogenic composition of claim 27, which further comprises a physiologically-acceptable vehicle. 29. The immunogenic composition of claim 27, which further comprises an effective amount of an adjuvant. 30. The immunogenic composition of claim 27 wherein each polypeptide is capable of generating an antibody that specifically recognizes said polypeptide, and wherein the amount of said immunogenic composition is effective to prevent or ameliorate colonization or infection by β-hemolytic streptococci in a susceptible animal. 31. The immunogenic composition of claim 30, which further comprises a physiologically-acceptable vehicle. 32. The immunogenic composition of claim 30, which further comprises an effective amount of an adjuvant. 33. The immunogenic composition of claim 30, wherein the β-hemolytic streptococci is Group A streptococci. 34. The immunogenic composition of claim 33, wherein the Group A streptococci is Streptococcus pyogenes. 35. The immunogenic composition of claim 9, further an effective amount of a polypeptide having (a) an amino acid sequence of SEQ ID NO: 6,(b) an amino acid sequence of SEQ ID NO: 10, or(c) an amino acid sequence of SEQ ID NO: 6 and an amino acid sequence of SEQ ID NO: 10. 36. The immunogenic composition of claim 35, which further comprises a physiologically-acceptable vehicle. 37. The immunogenic composition of claim 35, which further comprises an effective amount of an adjuvant. 38. The immunogenic composition of claim 35 wherein each polypeptide is capable of generating an antibody that specifically recognizes said polypeptide, and wherein the amount of said immunogenic composition is effective to prevent or ameliorate colonization or infection by β-hemolytic streptococci in a susceptible animal. 39. The immunogenic composition of claim 38, which further comprises a physiologically-acceptable vehicle. 40. The immunogenic composition of claim 38, which further comprises an effective amount of an adjuvant. 41. The immunogenic composition of claim 38, wherein the β-hemolytic streptococci is Group A streptococci. 42. The immunogenic composition of claim 41, wherein the Group A streptococci is Streptococcus pyogenes. 43. A method of treating a susceptible animal against colonization or infection by β-hemolytic streptococci comprising administering to the animal an effective amount of the immunogenic composition of claim 27, wherein each polypeptide is capable of generating an antibody specific to said polypeptide, and wherein the amount of said immunogenic composition is effective to ameliorate colonization or infection by β-hemolytic streptococci in the susceptible animal. 44. The method of claim 43, wherein the immunogenic composition is administered by subcutaneous injection, by intramuscular injection, by oral ingestion, intranasally, or combinations thereof. 45. The method of claim 43 wherein the β-hemolytic streptococci is Group A streptococci. 46. The method of claim 45 wherein the Group A streptococci is Streptococcus pyogenes. 47. The method of claim 43 wherein the animal is a human. 48. A method of treating a susceptible animal against colonization or infection by β-hemolytic streptococci comprising administering to the animal an effective amount of the immunogenic composition of claim 35, wherein each polypeptide is capable of generating an antibody specific to said polypeptide, and wherein the amount of said immunogenic composition is effective to ameliorate colonization or infection by β-hemolytic streptococci in the susceptible animal. 49. The method of claim 48, wherein the immunogenic composition is administered by subcutaneous injection, by intramuscular injection, by oral ingestion, intranasally, or combinations thereof. 50. The method of claim 48 wherein the β-hemolytic streptococci is Group A streptococci. 51. The method of claim 50 wherein the Group A streptococci is Streptococcus pyogenes. 52. The method of claim 48 wherein the animal is a human.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (47)
Muzyczka Nicholas (Stony Brook NY) Hermonat Paul L. (Bethesda MD) Berns Kenneth I. (Mamaroneck NY) Samulski Richard J. (Princeton NJ), AAV transduction vectors.
Conlon ; III Paul J. (Seattle WA) Grabstein Kenneth H. (Seattle WA), Activation of macrophage tumoricidal activity by granulocyte-macrophage colony stimulating factor.
Felgner Philip L. (Rancho Santa Fe CA) Kumar Raj (San Diego CA) Basava Channa (San Diego CA) Border Richard C. (Poway CA) Hwang-Felgner Jiin-Yu (Rancho Santa Fe CA), Cationic lipids for intracellular delivery of biologically active molecules.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Delivery of exogenous DNA sequences in a mammal.
Lelental Mark ; Noonan John M. ; Young Ralph H., Formulations for preparing metal oxide-based pigment-binder transparent electrically conductive layers.
Anderson Porter W. (Rochester NY) Eby Ronald J. (Rochester NY), Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad.
Felgner Philip L. (Rancho Santa Fe CA) Wolff Jon A. (Madison WI) Rhodes Gary H. (Leucadia CA) Malone Robert W. (Chicago IL) Carson Dennis A. (Del Mar CA), Induction of a protective immune response in a mammal by injecting a DNA sequence.
Johnston Robert E. (Chapel Hill NC) Davis Nancy L. (Chapel Hill NC) Smith Jonathan F. (Sabillasville MD) Grieder Franziska B. (Bethesda MD), Method of inducing an immune response with a live Venezuelan Equine Encephalitis virus expressing a heterologous immunog.
Dodge, Ingrid Lea; Anderson, Annaliesa Sybil; Hagen, Michael; Olmsted, Stephen Bruce, Multicomponent immunogenic composition for the prevention of beta-hemolytic streptococcal (BHS) disease.
Boutin Raymond H., Multifunctional complexes for gene transfer into cells comprising a nucleic acid bound to a polyamine and having a endosome disruption agent.
Gilmour Neil J. L. (Falkirk GB6) Martin William B. (Longniddry GB6) Sharp James M. (Haddington GB6) Thompson Dennis A. (Hayes GB2) Wells Peter W. (Haddington GB6), Pasteurellosis vaccines.
Beachey Edwin H. (Memphis TN) Poirier Thomas P. (Memphis TN) Kehoe Michael A. (Durham GB2), Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically en.
Beachey Edwin H. (Memphis TN) Poirier Thomas P. (Memphis TN) Kehoe Michael A. (Durham GB2), Therapeutic compositions against streptococcal infections, transformed hosts, methods of immunization and genetically en.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.